Press "Enter" to skip to content

Glenmark inks pact with South Korea’s Yuhan Corp to commercialise Ryaltris

Drug major Glenmark Pharmaceuticals Thursday said its Suisse subsidiary Glenmark Specialty S.A. has entered into an exclusive licensing agreement with South Korea’s Yuhan Corporation for commercialising its nasal spray Ryaltris.

Original source:

Also Read:   Sanofi, Regeneron begin testing arthritis drug as coronavirus treatment